Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 7, 2014, Pages 405-416

  El Assal, Mona I ^a   Helmy, Sally A ^b,c  

^a FUTURE UNIVERSITY IN EGYPT   (Egypt)

^b Damanhour University   (Egypt)

^c TAIBAH UNIVERSITY   (Saudi Arabia)

Author keywords

dosing adjustment; hemodialysis; linezolid; pharmacokinetics

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG EXPOSURE; EGYPTIAN; END STAGE RENAL DISEASE; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INVESTIGATIVE PROCEDURES; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; RANDOMIZED CONTROLLED TRIAL; RENAL IMPAIRMENT; SINGLE DRUG DOSE; URINARY EXCRETION; VALIDATION STUDY; BLOOD; CRITICAL ILLNESS; FEMALE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

ACETAMIDES; ADULT; CRITICAL ILLNESS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXAZOLIDINONES; RENAL DIALYSIS; YOUNG ADULT;

EID: 84908461024     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1910     Document Type: Article

References (28)

1. Clemett D, Markham A,. Linezolid. Drugs 2000; 59: 815-882.
2. Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr,. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1998; 32: 1341-1346.
3. Welshman IR, Stalker DI, Wajsczuk CP,. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Anti-Infect Drugs Chemother 1998; 16 (Suppl 1): 54.
4. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DHJ,. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-1246.
5. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R,. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-1845.
6. Slatter JG, Stalker DJ, Feenstra KL, et al., Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of 14C linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-1145.
7. Helmy SA,. Pharmacokinetics and relative bioavailability evaluation of linezolid suspension and tablet formulations. Drug Res 2013; 63 (9): 489-494.
8. Cattaneo D, Baldelli S, Conti F, Cozzi V, Clementi E,. Determination of linezolid in human plasma by high performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2010; 32: 520-524.
9. Brier ME, Stalker DJ, Aronoff GR, et al., Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47 (9): 2775-2780.
10. Zyvox® Investigational Medicinal Product. Last revision July 2008. Available at: http://media.pfizer.com/files/products/uspi-zyvox.pdf. [Accessed 10 September 2009].
11. Rodriguez Colomo O, Álvarez Lerma F, González Pérez MI, Sirvent JM, García SM,. Study Group of Infection in Critical Patients. Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function. Eur J Clin Microbiol Infect Dis 2011; 30 (5): 635-643.
12. Tsuji Y, Hiraki Y, Mizoguchi A, et al., Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008; 14 (2): 156-160.
13. U.S. Food and Drug Administration Centre for Drug Evaluation and Research (FDA). Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function. Study Design, Data Analysis, and Impact on Dosing and Labeling, Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, March 2010. http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. [Last accessed 28 May 2014].
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice: http://www.ikev.org/haber/ stabilite/cd/14%201.13%20ICH%20M4%20CTD%20 for%20CD.pdf. [Accessed 23 August 2010].
15. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Huang V, Gortney JS,. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 26 (12): 1784-1793.
17. US Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical method validation. http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM070107.pdf. [Accessed 13 November 2008].
18. Gibaldi M, Perrier D,. Pharmacokinetics. Marcel Dekker: New York, 1982.
19. Hedaya MA,. Basic Pharmacokinetics. Taylor and Francis group: Boca Raton, FL, 2007.
20. U.S. Food and Drug Administration Centre for Drug Evaluation and Research (FDA). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, March2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. [Last accessed 3 January 2013].
21. Westlake WF,. Use of confidence interval in analysis of comparative bioavailability trials. J Pharm Sci 1972; 61: 1340-1341.
22. Chien JW, Kucia ML, Salata RA,. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infection. Clin Infect Dis 2000; 30: 146-151.
23. von Baum H, Schehl J, Geiss HK, Schaefer F,. Prevalence of vancomycin-resistant enterococci among children with end-stage renal failure. Clin Infect Dis 1999; 29: 912-916.
24. Dipiro J, Talbert B, Yee GC, Matzke GR, Wells BG, Posey LM, (eds). Pharmacotherapy: A Pathophysiologic Approach, 7th edn. McGraw-Hill, New York, 2008.
25. Sasaki T, Takane H, Ogawa K, et al., Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011; 55 (5): 1867-1873.
26. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ,. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003; 47 (2): 548-553.
27. Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ,. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti-infective Ther 2008; 6 (6): 825-848.
28. Florian T, Josef K, Ibrahim E-M, Alexander R, Helinz B,. A comparison of polysulfone and cellulose acetate hemodialyzers. Am J Kid Disease 1998; 32 (40): 642-645.